Sign In
Buy RANI
$0.774
-0.0462 (-5.63%)
At Close: Jul 31, 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
09:00am, Tuesday, 15'th Jul 2025
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Announces Research Agreement with Chugai
08:00am, Monday, 19'th May 2025
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
04:05pm, Tuesday, 13'th May 2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
07:15pm, Monday, 31'st Mar 2025
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Co
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
04:05pm, Monday, 31'st Mar 2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
06:00pm, Tuesday, 25'th Mar 2025
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
04:05pm, Tuesday, 08'th Oct 2024
SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the o
Rani Therapeutics to Participate in September Investor Conferences
04:05pm, Tuesday, 03'rd Sep 2024
SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
04:05pm, Tuesday, 06'th Aug 2024
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -
Rani Therapeutics to Participate in August Investor Conferences
04:05pm, Monday, 29'th Jul 2024
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
08:30am, Monday, 22'nd Jul 2024
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
07:00am, Monday, 24'th Jun 2024
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism w
